Safety And Disease Control Achieved With The Addition Of Nivolumab (Nivo) To Chemoradiotherapy (Crt) For Intermediate (Ir) And High-Risk (Hr) Local-Regionally Advanced Head And Neck Squamous Cell Carcinoma (Hnscc): Rtog Foundation 3504.
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要